Daniel Abaneme is building a research infrastructure to determine whether Artificial Intelligence (AI) works in American Healthcare

Sir: Most AI-in-healthcare works fixate on what the technology can do. Daniel Abaneme focuses on what it takes to make the technology work, and argues that limiting factor has never been the algorithms, but the infrastructure built around them. In doing so, he has identified, perhaps, the most overlooked bottleneck in Healthcare AI; not the models themselves, but the research infrastructure, governance frameworks and operational scaffolding that determine whether those models ever touch a patient.

“AI doesn’t improve healthcare by existing,” Abaneme observed. “It improves healthcare when it’s designed to fit people, workflows and accountability structures.”

It is a perspective that could only come from someone who has spent years at the unglamorous intersection of federal science, health system operations, and Machine Learning (ML) research. Not theorising from the outside but building from within.

What distinguishes Abaneme’s approach from the typical AI-in-healthcare commentary is his professional formation. As a Research Programme Manager at CentraCare Health, one of Minnesota’s largest integrated health systems, he brings a pure combination of laboratory credibility and system-level thinking to problems that desperately need both.

His foundation was forged inside the federal research ecosystem. At the National Institute on Aging (part of the National Institute of Health), Abaneme led the establishment of over $500,000 high throughput proteomics workflow, a project that required not just scientific acumen but the orchestration of procurement, regulatory compliance, protocol development and cross-team coordination inside one of the most scrutinised research environments in the world.

Where biotech executives speak in pipeline milestones and AI researchers in benchmark scores, Abaneme speaks in research governance structures, IRB compliance pathways and implementation timelines.

His scholarly contributions reflect where he believes healthcare is heading. He is an author on ML research examining early disease detection in United States (U.S.) health systems, and a co-author on work exploring ML-enabled approaches to mental health assessment in post-pandemic populations. These are not vanity publications; they are working documents from someone actively testing whether AI outputs can be actionable inside real clinical environments.

Yet his most distinctive contribution is not the research itself but the translation layer he insists on building around it. “An algorithm that lives in a paper doesn’t save lives,” he says. “An algorithm embedded into care teams, with clear escalation paths and governance, can.’”

This practitioner-first sensibility mirrors broader shifts in how complex, regulated industries now evaluate innovation leaders – judged not by the novelty of their ideas but by their capacity to operationalise them responsibly, at scale, without regulatory misadventure.

A recurring argument in Abaneme’s work is that research operations are the hidden variables in Healthcare AI success. At CentraCare, he has built standardised research intake processes, IRB-ready protocol templates, governance standard operating procedures and portfolio dashboards that allow clinicians to move from a research idea to implementation without unnecessary friction.

The portfolio of this infrastructure now spans chronic disease management, nephrotoxin stewardship, concussion care models and patient-portal analytics. The common thread is not subject matter but structure; a reproducible architecture that makes rigorous research possible at scale.

“When research operations are weak, AI becomes risky,” ‘he explains. “When they’re strong, AI becomes safe, measurable and scalable.”

Despite the technical register of much of his work, Abaneme consistently returns to the workforce dimension of healthcare innovation. He has championed structured research internship programmes and mentorship pipelines aimed at cultivating the next generation of clinician-researchers and health data scientists. “Technology doesn’t build capacity; people do,”he says. “Our responsibility is to design systems that make people better at what they do, not smaller.”

Colleagues describe him as someone who translates complexity into clarity: executives understand why a dashboard matters; clinicians understand how it serves patients. That capacity to move fluidly between the language of science, the language of administration, and language of care is what separates leaders who merely deploy AI from those who make it work.

Like many professionals operating at the intersection of technology and governance, Abaneme has little patience for legacy success metrics. “Being on time and on budget is the baseline,” he says. “The real question is whether the work improved decisions, reduced inequities and built institutional capability.”

It is that broader definition of impact spanning AI research, healthcare delivery and the quiet but essential work of research systems design that places Abaneme within a growing cohort of cross-disciplinary professionals reshaping how complex organisations think about innovation.

As American healthcare continues to grapple with rising demand, workforce strain and the unresolved ethical challenges posed by large-scale AI deployment, figures like Abaneme are increasingly consequential not because they promise disruption, but because they offer something more durable: integration accountability, and the institutional foresight to know that the hardest problem are never purely technical.

Chika Onwuji, a public affairs analyst, wrote from Lagos.